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Abstract
Background: Protein-protein interactions play a major role in Cancer Control 
and their detailed understanding by Label-Free Nanotechnology is essential 
especially within the framework of a personalized medicine-based approach. 
Material and Methods: We implemented an array of label-free 
nanobiotechnologies, including the Quartz Crystal Microbalance with 
Dissipation factor monitoring (QCM_D). We used it for the conductometric 
monitoring of an antiblastic (temozolomide) interacting with genes and proteins, 
such as MLH1, that represents a biomarker of the rate survival of patients 
suffering from brain tumors, outcome of chemotherapy and resistance to drug 
itself. We coupled the Nucleic Acid Programmable Protein Arrays (NAPPA) 
and the cell-free protein array with the quartz crystal microbalance technology. 
In another proof of principle, we coupled the NAPPA with the SNAP tag E. coli 
cell-free expression system. The goal is to analyze the protein-protein interaction 
using Matrix Assisted Laser Desorption Ionization Time-of-Flight (MALDI-
TOF) Bruker Ultraflex and “Protein synthesis Using Recombinant Elements” 
(PURE) system, thus avoiding the “black box” nature of the cell extract. The E. 
coli in vitro transcription/translation system (IVTT) in respect to the reticulocyte 
lysate (RRL) or human lysate (HL) is totally characterized and represents an 
advantage for the subsequent mass spectrometry (MS) analysis. An R Script for 
Mass Spectrometry Data Preprocessing before Data Mining (SpADS) provides 
the user with peak recognition and amplitude independent subtraction functions. 
The MS samples are obtained from SNAP-NAPPA spots and printed on gold 
coated glass slides in higher density, in order to obtain an amount of protein 
appropriate for MS analysis. 
Conclusion: We developed a coherent approach that overcome the drawbacks and 
pitfalls of the traditional laborious and time-consuming labeled and fluorescence-
based experimental procedures. This, taken together with the unique properties of 
proteins obtained with Langmuir-Blodgett (LB)-based crystallography that can 
enable new strategies for drug design separately reported, defines our approach 
to cancer control.
Keywords
Brain cancer, Cell-free expression system, Conductometer, Nucleic Acid 
Programmable Protein Array (NAPPA), Quartz Crystal Microbalance with 
Dissipation factor Monitoring (QCM_D), Temozolomide
NanoWorld Journal   |   Volume 1 Issue 1, 2015 9
Determination of Protein-Protein Interaction for Cancer Control via
Mass Spectrometry and Nanoconductimetry of NAPPA SNAP Arrays: An Overview Nicolini et al.
underpin the list of most significantly interconnected genes, 
termed as hub genes or leader genes (Figures 2 and 3). This 
algorithm has been exploited to shed light on the molecular 
mechanisms of tolerance to kidney transplant, showing 
the gene interaction network expanded around TMTC3/
SMILE, a gene differentially expressed in transplanted 
immunosuppressive-free subjects [15]. Some of these genes 
(HTATIP/KAT5, ARRB2 and ATF2) have been rarely 
described as predictors of clinical outcome to renal graft in the 
extant literature, whilst the others (c-JUN, TP53, MAPK14, 
XBP1 and NPHS1) were already known to be associated 
with kidney transplant. The panel made up of the previously 
computed hub genes has been validated mining the Gene 
Expression Omnibus (GEO) database, a publically available 
repository of gene microarrays. The pooled analysis of their 
expression has confirmed their relevance in the biological 
processes leading to tolerance to kidney allograft, both for the 
expression in blood and in kidney tissue. Gene Ontology (GO) 
analysis has enabled to investigate the main pathways involved 
in the response to kidney transplant (Figure 2). The Pearson 
statistical analysis has shown correlation between expression 
in blood and in kidney tissue (Figure 3) [16].
Introduction
Together with gene-gene and gene-protein interactions, 
protein-protein, gene-drug [1-2] and protein-drug [3-
4] interactions play a major role in the field of molecular 
pharmacology as their detailed understanding is essential for 
improving the mechanisms of the drug itself and to design 
new chemical compounds, especially within the framework of 
a personalized medicine-based approach [5-6].
Figure 1: Protocol of the integrated approach for personalized oncology. After collecting the samples from patients (tissue biopsies, blood or other fluids), differentially 
expressed genes (DEG) are studied using the Leader Gene Algorithm (LGA). Thus, only few genes of interest are selected (genomics signature), which can be used 
as a panel for monitoring the diseases or can be subsequently expressed via the Nucleic Acid Programmable Protein Array (NAPPA) technology to fully characterize 
protein–protein interactions (proteomics signature) via label-free nanobiotechnologies (namely, Quartz Crystal Microbalance with Dissipation Factor Monitoring 
(QCM_D), Anodic Porous Allumina (APA), mass spectrometry (MS)) overcoming the limitations and difficulties encountered in the use of labeled technologies. The 
unique properties of proteins obtained using the Langmuir-Blodgett (LB)-based crystallography enable optimal drug design.
Our laboratory had previously introduced novel approaches 
in the field of nanogenomics [7-9] and nanoproteomics [10-
11], pioneering in both fields. Only by coupling and combining 
proteomics and genomics within a highly integrated, coherent 
framework, with an emphasis on proteomics, clinical problems 
can be successfully addressed (Figure 1) [12-13].
Mass-scale genomics enables to study the expression of 
thousands of genes at the same time using high-throughput 
technologies. However, the analysis and interpretation of the 
produced data is not a simple task.
The “LeaderGene algorithm” approach [14], which is a 
candidate gene prioritization algorithm, indeed enables to 
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Genomics alone is not able to shed light on complex 
biological processes if not extensively coupled with proteomics. 
Nucleic Acid Protein Programmable Arrays (NAPPA) 
represents the necessary step further, being a bridge between 
genomics and proteomics. It enables to study proteins from 
the expression of selected genes (Figure 4), both with labeled 
technologies (Figure 4, above) and with label-free devices 
(Figure 4, below) [17, 18]. These selected genes can be the 
genes obtained with the previously mentioned candidate gene 
prioritization algorithm or similar approaches.
Recently, we coupled NAPPA with the Quartz Crystal 
Microbalance (QCM) with Dissipation factor (D factor) 
monitoring (QCM_D), showing that we are able to 
distinguish among different proteins, each one having its 
unique conductance curve [19]. Besides performing the 
genomics and proteomics task, NAPPA-based QCM_D 
enables to investigate and perform both pharmacogenomics 
and pharmacoproteomics tasks in a very effective, quick (only 
few minutes) and cheap way, making it particularly attractive 
for clinical uses.
Of particular clinical interest is indeed the pharmacodynamics 
and pharmacokinetics characterization of antiblastic drugs as 
cancer is one of the major issues to be still addressed in the 
field of clinical biomedicine [20].
In particular, brain tumor is one of the most aggressive 
forms of cancer.
Temoz o lomide(3-Methy l-4-oxo-3 ,4-d ihydro-
imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide; 
brand name Temodar, Temodal and Temcad) is an oral 
antiblastic, chemically being the imidazotetrazine derivative of 
the alkylating/methylating agent dacarbazine and undergoing 
rapid chemical conversion in the systemic circulation at 
physiological pH to the active compound 3-methyl-(triazen-
1-yl)imidazole-4-carboxamide (MTIC). Temozolomide 
is useful for treating brain tumors, such as the grade IV 
astrocytoma or glioblastoma multiforme, the relapsed grade 
III anaplastic astrocytoma, especially if nitrosourea- and 
procarbazine-refractory, as well as skin cancers like melanoma 
and the fungoides mycosis/Sézary syndrome. It is currently 
in evaluation for the treatment of other tumors, such as the 
relapsed primary central nervous system (CNS) lymphoma, 
recurrent glioma and oligodendroglioma (in the last case, 
replacing the classical regimen PCV, i.e. procarbazine-
lomustine-vincristine). When it binds to the DNA, usually at 
the N-7 or O-6 positions of guanine residues, it produces O6-
methylguanine (O6MG) and this abduct causes the activation 
of futile DNA mismatch repair (MMR), as well as DNA 
double-strand breaks (DSBs), G(2) arrest and ultimately 
Figure 3: Differentially expressed genes (DEGs) involved in the process of tolerance to kidney allograft, as discovered exploiting Leader Gene Algorithm (LGA), 
validated mining the Gene Expression Omnibus (GEO) repository of gene microarrays (Left). The Pearson’s correlation plot shows the statistically significant 
correlation between expression in blood and in kidney tissue (Right).
Figure 2: The genomics branch of the previously (Figure 1) introduced protocol of integrated nanoproteogenomics approach (left) and an example of application to 
kidney transplant (right) showing the pathways involved in the tolerance process to kidney allograft. 
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cell death. The activation of the molecular mechanisms of 
MMR is quite a complex biological process that requires 
different protein-protein interactions, such as the Mre11/
Rad50/Nbs1 (MRN complex), the Proliferating Cellular 
Nuclear Antigen (PCNA) complex and the gamma-H2AX 
and 53BP1 foci [21]. Unfortunately, some cells can escape 
from this mechanism producing a protein known as O6-
alkylguanine DNA alkyltransferase (AGT), encoded by the 
O6-methylguanine-DNA methyltransferase (MGMT) gene. 
Recently, scientists have been able to find and characterize 
some biomarkers of resistance to temozolomide, such as 
MLH1, which is also an important marker of survival rate in 
patients with glioblastoma [21-25].
Another innovative approach we developed is given 
by coupling NAPPA with the SNAP tag Escherichia coli 
coupled cell-free expression system and Mass Spectrometry 
(MS) (in particular, the Matrix Assisted Laser Desorption 
Ionization Time-of-Flight (MALDI-TOF) Bruker Ultraflex) 
with the goal of implementing a standardized procedure of 
identification of biomarkers in clinical settings and to analyze 
the protein-protein interaction occurred on NAPPA array 
using label-free technology [26]. We employed the process 
“Protein synthesis Using Recombinant Elements” (PURE) 
system, which, due to its high complexity, needs ad hoc in-
house developed bioinformatics tools to be analyzed. The 
PURE system represents a step towards a totally defined in 
vitro transcription/translation system (IVTT), thus avoiding 
the “black box” nature of the cell extract. The immediate 
advantage is the significantly reduced level of all contaminating 
activities and the Escherichia coli IVTT machinery in respect 
to the rabbit reticulocyte lysate (RRL) or human lysate, which 
is totally characterized and thereby represents an advantage 
for the subsequent MS analysis of the results. The presence of 
“background” molecules, in fact, represents the main obstacle 
to these MS data interpretation. For this latter reason “An 
R Script for Mass Spectrometry Data Preprocessing before 
Data Mining” (SpADS) was implemented [27]. SpADS 
provides useful pre-processing functions, such as binning, 
peak extractions, spectra background subtraction and dataset 
managing. Moreover, in its final version, it is able to perform 
peak recognition, as well as amplitude independent subtraction. 
The MS samples are obtained from SNAP-NAPPA spots 
printed on gold coated glass slides in higher density, in order 
to obtain an amount of protein appropriate and suitable for 
MS analysis. Spots of 300 microns were printed in 12 boxes, 
each box with 100 identical spots. The sample of immobilized 
genes used as test cases were all of clinical interest and 
implicated in the process of mutagenesis and carcinogenesis: 
namely, p53_human (cellular tumor antigen p53); CDK2_
human (cyclin-dependent kinase type 2); SRC_human-SH2 
(the SH2 domain of proto-oncogene tyrosine-protein kinase), 
PTPN11 (human-SH2, the SH2 domain of tyrosine-protein 
phosphatase non-receptor type 11).
Materials and Methods
QCM_D nanoconductimetry
The QCM_D instrument was developed by Elbatech 
(Elbatech srl, Marciana – LI, Italy). The quartz was connected 
to a radio frequency (RF) gain-phase detector (Analog 
Devices, Inc., Norwood, MA, USA) and was driven by a 
precision direct digital synthesis (DDS; Analog Devices, Inc.) 
around its resonance frequency, thus acquiring a conductance 
versus frequency curve (“conductance curve”) that shows a 
typical Gaussian behaviour. The conductance curve peak 
was at the actual resonance frequency, while the shape of the 
curve indicated how the viscoelastic effects of the surrounding 
layers affected the oscillation. The QCM_D software, 
QCMAgic-Q5.3.256 (Elbatech srl), allows to acquire the 
conductance curve or the frequency and dissipation factor 
variation versus time. In order to have a stable control of the 
temperature, experiments were conduced in a temperature 
chamber. Microarrays were produced on standard 
nanogravimetry quartz used as highly sensitive transducers. 
The QC expressing proteins consisted of 9.5 MHz, AT-cut 
quartz crystal of 14 mm blank diameter and 7.5 mm electrode 
Figure 4: Schematic representation of Nucleic Acid Programmable Protein Arrays (NAPPA) technology for Mass Spectrometry (MS) with SNAP. In each spot a 
mixture of plasmid DNA, BSA and anti-GST antibodies is printed and immobilized on cysteamine coated surface. The antibody is responsible for the capture of the 
freshly expressed proteins that are tagged, at one of their ends, with a GST tail. The proteins are translated using an in vitro transcription–translation system (IVTT) 
(top). Fluorescence-based technologies (top, right) and label-free technologies, namely Quartz Crystal Microbalance with Dissipation Monitoring (QCM_D) 
coupled with NAPPA and Mass Spectrometry (MS) (bottom).
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diameter, produced by ICM (Oklahoma City, OK, USA). The 
electrode material was 100 Å Cr and 1,000 Å Au and the quartz 
was embedded into glass-like structures for easy handling. The 
NAPPA-QC arrays were printed with 100 spots per QC. 
Quartz gold surfaces were coated with cysteamine to allow the 
immobilization of the NAPPA printing mix. Briefly, quartzes 
were washed three times with ethanol, dried with Argon and 
incubated overnight at 4°C with 2 mM cysteamine. Quartzes 
were then washed three times with ethanol to remove any 
unbound cysteamine and dried with Argon. Plasmid DNA 
coding for GST tagged proteins were transformed into E. 
coli and the DNA was purified using the NucleoPrepII anion 
exchange resin (Macherey Nagel, Inc., Bethlehem, PA, USA). 
The NAPPA printing mix was prepared with 1.4 μg/μl DNA, 
3.75 μg/μl BSA (Sigma-Aldrich, Milan, Italy), 5 mM BS3 
(Pierce, Rockford, IL, USA) and 66.5 μg polyclonal capture 
GST antibody (GE Healthcare Life Sciences, Piscataway 
Township, NJ, USA). Negative controls, named master mix 
(hereinafter abbreviated as “MM”), were obtained replacing 
DNA for water in the printing mix. Samples were incubated at 
room temperature for 1 hour with agitation and then printed 
on the cysteamine-coated gold quartz using the Qarray II from 
Genetix. In order to enhance the sensitivity, each quartz was 
printed with 100 identical features of 300 microns diameter 
each, spaced by 350 microns center-to-center. 
The human cDNAs immobilized on the NAPPA-QC 
were: CYP11A1 (cytochrome P450, Family 11, Subfamily A, 
Polypeptide 1), MLH1 (mutL homolog 1) and POLB (a DNA 
polymerase). Gene expression was performed immediately 
before the assay following the protocol described in more 
details in our previous articles. Briefly, in vitro transcription 
and translation were performed using HeLa lysate mix (1-Step 
Human Coupled IVTT Kit; Thermo Fisher Scientific Inc.), 
prepared according to the manufacturers’ instructions. The 
quartz, connected to the nanogravimeter inside the incubator, 
was incubated for 10 min at 30°C with 40 μl of HeLa lysate mix 
for protein synthesis and, then, the temperature was decreased 
to 15°C for a period of 5 min to facilitate protein binding on 
the capture antibody (anti-GST). After the protein expression 
and capture, the quartz was removed from the instrument 
and washed 3 times at room temperature in 500 mM NaCl 
PBS. The protocol described above was followed identically 
for both negative control QC (the one with only MM, i.e, 
all the NAPPA chemistry except the cDNA) and protein 
displaying QC. After protein expression, capture and washing, 
the QCs were used for the interaction studies. QC displaying 
the expressed protein was spotted with 40 μl of protein/drug 
solutions in PBS at increasing concentrations at 22°C.
We analyzed the interaction between CYP11A1 
and cholesterol, both in solution and in blood, to acquire 
information on the binding kinetics. After protein expression 
and capture, CYP11A1-expressing QC was positioned in the 
flow chamber and exposed to a flow of a 50 μM cholesterol 
(Sigma-Aldrich) solution in 30% sodium cholate (Sigma-
Aldrich) at 0.02 ml/min flow rate for 10 min at 22°C. We 
used cytochrome P450scc (CYP11A1) for the detection of 
cholesterol (Sigma-Aldrich) because of its specificity.
For the pharmacoproteomic experiment, we also tested 
the possibility to analyze drug-protein interactions in QC 
displaying multiple proteins. For this aim, we co-printed 
cDNA for POLB and MLH1 on a single QC. We analyzed the 
interaction response to Temodar on both NAPPA-expressed 
QCs. We analyzed the interaction between MLH1, pol B and 
temozolomide drug solutions at different concentrations to 
analyze the binding kinetics.  After protein expression and 
capture, the expressing QC was spotted, in sequence, with 
40 μl of temozolomide solutions of 1 μg/ml, 2 μg/ml, 5 μg/
ml, 10 μg/ml, 20 μg/ml, 50 μg/ml, 100 μg/ml and 200 μg/ml 
concentration. 
MS of NAPPA SNAP
As far as the MS experiments are concerned, we analyzed 
by MALDI-TOF MS four copies of SNAP-NAPPA slides 
with 7×7 spots per box and four copies of slides with 10×10 
spots per box. The results were extremely reproducible both with 
respect to 7×7 spots/box and 10x10 spots/box that with respect 
to the different spectrometers and no significant difference 
was appreciable. We conducted two parallel identifications, 
the first through the matching algorithm comparing blinded 
and known samples in the experimental mass lists and the 
second submitting experimental mass lists to databank search. 
We submitted the experimental mass list obtained for the 
known samples (p53, CDK2, Src-SH2 and PTPN11- SH2) 
to MASCOT data bank search. The matching of the results 
in human database allowed us to identify with a good score 
albumin (ALBU_HUMAN serum albumin) presumably due 
to some peptides that are common also to BSA. No other 
human proteins were identified. We performed a search 
against bacterial database; for all the samples we identified 
approximately the same proteins (essentially from the 
bacterial lysate). MALDI-TOF data analysis Data identified 
essentially proteins from SNAP-NAPPA chemistry and from 
bacterial lysate. These results were not surprising considering 
the background signal and the high complexity of the spectra 
of the analyzed samples. Moreover, one should bear in mind 
that the concentration of the proteins expressed and captured 
on the array is, at least in solution; hundred times lower than 
those of E. coli lysate components.
Results and Discussion
As already extensively explained in our previous articles 
[9, 11-13, 17-19], QCM_D measures were calibrated both 
for frequency and for D factor shifts. The calibration curve 
equations (obtained with Ordinary Least Squares methods, 
OLS) are: 
Δf= - 7.16 – 231.18 m; with r2= 0.9986, 
and D = 0.831 + 0.286 η; with r2= 0.9990. 
We analyzed the conductance curves acquired in NAPPA-
QCs in different steps of the expressing and capturing process: 
after the addition of human IVTT lysate at 30°C (“IVTT 
addition”), i.e. prior protein expression; after 10 minutes 
from the addition of human IVTT lysate, i.e. after protein 
expression (“IVTT addition 10 min”); after the final washing 
process with PBS (“Post-wash”).
Conductometric monitoring of enzyme-substrate and 
drug-protein interactions is of fundamental importance in the 
field of molecular pharmacology. 
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The P450scc-cholesterol interaction has been well 
characterized in the extant literature and the results obtained 
have been satisfactorily compared with those in literature [28]. 
From Figure 5, left, the decrease in the frequency (f) due 
to the human IVTT lysate addition is evident. There is also a 
change in the viscoelastic properties of the quartzes after the 
human IVTT lysate addition leading to a measurable increase 
of the bandwidth (Γ). During the incubation, on the contrary, 
the frequency and bandwidth variations were minimal. This 
effect could be related to two main causes: first, merely due 
to the IVTT lysate addition on the QC surface - when the 
QC comes in contact with a solution the frequency decreases 
depending upon the viscosity and the density of the solution 
and there is a decrement in damping the resonant oscillation 
- and the second, due to the change of the composition of 
both QC surface and IVTT lysate after gene expression, 
protein synthesis and immobilization. The conductance curves 
acquired after PBS washing evidenced the further changes of 
solution in contact with the QC.
Figure 5: QCM_D conductance curves for CYP11A1-sterol interaction both in 
static (left) and in flow (right) conditions. Equation for mathematical modeling 
and data analysis is also shown (bottom, left).
Our QCM_D instrument gave us the opportunity to 
monitor in real-time the trend of D factor and f. In Figure 5, 
right, we reported frequency vs. time during the interaction 
between CYP11A1 and cholesterol in solution. Using the 
equation shown in Figure 5 to fit this experimental data in 
solution, we obtained a K of about 100 μM, a value in good 
agreement with the values found in the literature (17 and 
earlier). 
Bioinformatic predictions (Figure 6) of genes interacting 
with temozolomide using 
STITCH (http://stitch.embl.de/) and molecular 
modeling of protein-drug interaction 
(Figure 7) are finally utilized to guide and interpret 
results from QCM_D instrument in carrying out multi-gene 
experimentation among MLH1 and temozolomide.Figure 6: Bioinformatics predictions of genes interacting with temozolomide 
(using STITCH, http://stitch.embl.de/).
Figures 8 and 9 depict the conductance curves of reference 
quartz (master mix) plus temozolomide solutions at increasing 
concentrations (Figure 8) and the conductance curves for 
two NAPPA-QCs co-expressing MLH1 and POLB (Figure 
9, multi-gene experiment). These data pointed to a unique 
conductance curve shape for each protein and suggested the 
possibility to identify the expressed proteins by QCM-D even 
when combined on the same expressing QC.
Moreover, we assessed the reproducibility of the QCM_D 
measurements, computing the coefficient of variation (CV, or 
σ*) for each experiment using the following equation: 
σ* = σ/μ, 
where σ is the standard deviation and μ is the mean. 
CV values are usually very low, confirming the repeatability 
of the experiments and the validity and portability of the 
technique. In our hands, NAPPA-based QCM_D proved to 
have an intra-assay overall CV of 5 % (range, 3.3 -8.0 %).
Figure 7: Bioinformatics molecular modeling of protein-drug interaction (MLH1 
and temozolomide).
The MS coupled with ad hoc-implemented bioinformatics, 
as it was expected due to the high complexity of the NAPPA-
SNAP system, gave quite encouraging results improving 
earlier findings with MS without SNAP that were very 
complex and, thus, a bioinformatics tool had to be developed 
ad hoc for their analysis. The MS samples were realized by 
printing SNAP-NAPPA spots on gold coated glass slides in 
a special geometry in order to obtain an amount of protein 
appropriate for MS analysis. The samples were printed in 12 
boxes of 7×7 spots per box. One box apiece was reserved to the 
sample genes (p53, CDK2, SH2-Src and SH2-PTPN11), two 
boxes were negative controls (MM) and reference samples, 
while six boxes were printed with the sample genes in an order 
blinded to the researcher who performed the MS analysis. We 
conducted two parallel identifications, the first through the 
matching algorithm comparing blinded and known samples 
in the experimental mass lists and the second submitting 
experimental mass lists to databank search. The databank 
search of samples in the experimental mass lists obtained by 
MALDI-TOF or LC-ESI-MS provided the identification, 
with significant scores, of molecules of MM or E. coli lysate 
(Figure 4). Different strategies have been addressed to overcome 
the presence of these “background” molecules that represented 
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the main obstacle to the sample identification. Experimental 
master mix plus E. coli lysate mass lists have been subtracted to 
samples of the experimental mass lists and the results have been 
submitted to MASCOT databank search. Unfortunately, this 
strategy did not give statistically significant results on MS of 
these SNAP NAPPA arrays, with the best identification being 
22% for the CDK2 sample and poor clustering even on known 
proteins, apparently worse if compared with those relative to 
the old MS NAPPA version, presented by Spera et al. [29]. 
By pursuing the coupling of our newly developed software 
SpADS to K Means Cluster algorithm we obtained good 
results both for known and unknown protein identification, 
up to 67% correct score, quite better than earlier MS without 
SNAP. A conservative rule of thumb suggests that using at 
least hundred times more MS spectra it is possible to identify 
the unknown protein (a minimum of hundred rather than 1 
as was in the limiting worst case and rather than 8 as was in 
the best case). The results obtained to this point are, thereby, 
encouraging even with a quite low number of MS spectra so 
far acquired and without the subtraction of ab initio known 
MS spectra of E. coli lysate. As we have recently shown in 
more detail [30], the performed subtraction of the theoretical 
values of some lysate recombinant E. coli components, at least 
partially, from the experimental MS spectra, gave promising 
results (Figure 10).
Figure 8: QCM_D conductance curves for MM_MLH1 interacting with 
temozolomide at increasing concentrations.
Conclusions
We developed a coherent approach by integrating 
genomics and proteomics that could overcome the drawbacks 
and pitfalls of the traditional laborious and time-consuming 
labeled and fluorescence-based experimental procedures. 
This, taken together with the unique properties of proteins 
obtained with Langmuir-Blodgett (LB)-based crystallography 
[31-38] that can enable new strategies for drug design (work 
in progress), makes the goal of cancer control tremendously 
ambitious.
QCM_D enables scientists and physicians to test 
chemical-proteins in a quick and effective way. Summarizing 
all the experiments we have so far carried out, QCM_D is able 
to discriminate among dozens of molecules and chemicals, 
each one having its unique conductance curve shape. Being 
label-free, QCM_D is extremely powerful and promising in 
cancer control. We presented the results obtained applying 
our innovative conductometer realized by combining NAPPA 
technology with QCM_D, for the characterization of 
protein-protein, protein-sterol and protein-drug interactions 
in a multiparametric way taking advantage of the multiple 
information provided by the analysis of the conductance 
curves (i.e. conductance, viscoelasticity and adsorbed mass).
Figure 9: QCM_D conductance curves for MM_MLH1 and POLB interacting 
with temozolomide at increasing concentrations.
Moreover, through our conductometer, we acquired information 
on the kinetic constant of enzymatic interaction. Results about 
the sensitivity and selectivity of the original prototype have 
been extensively presented in previous papers that we have 
here reviewed. The data presented in this overview have been 
obtained employing a further improved version, both flow and 
static, of our conductometer. An interesting implication for 
potential clinical applications concerned the possibility to 
drastically reduce the time of protein expression and capture 
under our experimental conditions. We noticed that 15 
minutes after IVTT lysate addition peak frequency and 
bandwidth of the curves did not change, likewise after few 
minutes at 15°C, for protein capture. We deduced from these 
results that the protein expression took place in the first 
minutes and that also their capture needed only few minutes. 
The results presented seem to confirm our hypothesis. The 
conductance curves obtained showed that protein expression 
and capture, as well as protein-protein interactions were 
successfully performed. The QCM_D instrument we used 
allowed us to monitor in real-time the trend of D factor and f 
during the interaction between different molecules of high 
clinical interest, especially for oncologists, both in solution and 
in blood. We, thus, demonstrated the versatility of the 
NAPPA-QC biosensors for the detection of protein-protein 
interactions, protein-sterol and protein-drug interaction. Due 
to the simplicity with which new NAPPA-QC biosensors can 
be generated and to the successful application on clinical 
research [39], we envision the use of this platform for the 
development of biosensors for other applications, including, 
but not limited to, protein-small molecules, protein-lipids and 
protein-DNA.
Also, the ongoing research in the field of MS coupled 
with NAPPA and SNAP is giving, as shown recently [26, 30], 
encouraging results in the study of protein-protein interaction, 
a topic relevant for cancer control. We strongly believe that 
these efforts can be precious in the field of personalized 
oncology.
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Figure 10: MS-SNAP spectra (left) and MM spectra (as background, right) 
properly aligned.
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